Discovery and preclinical development of a potent epigenic editor targeting PCSK9 to lower LDL cholesterol.
作者信息
Xiong Qiang, Tremblay Frederic, Marlowe Jennifer
机构信息
nChroma Bio, Boston, MA 02215, USA.
nChroma Bio, Boston, MA 02215, USA.
出版信息
Mol Ther. 2025 May 7;33(5):1874-1875. doi: 10.1016/j.ymthe.2025.04.012. Epub 2025 Apr 22.
Abstract
摘要
相似文献
1
Discovery and preclinical development of a potent epigenic editor targeting PCSK9 to lower LDL cholesterol.
Mol Ther. 2025 May 7;33(5):1874-1875. doi: 10.1016/j.ymthe.2025.04.012. Epub 2025 Apr 22.
2
Therapeutic efficacy of PCSK9 monoclonal antibodies in statin-nonresponsive patients with hypercholesterolemia and dyslipidemia: A systematic review and meta-analysis.
Int J Cardiol. 2016 Nov 1;222:119-129. doi: 10.1016/j.ijcard.2016.07.239. Epub 2016 Jul 30.
4
A Systematic Review of PCSK9 Inhibitors Alirocumab and Evolocumab.
J Manag Care Spec Pharm. 2016 Jun;22(6):641-653q. doi: 10.18553/jmcp.2016.22.6.641.
5
PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.
Cochrane Database Syst Rev. 2017 Apr 28;4(4):CD011748. doi: 10.1002/14651858.CD011748.pub2.
6
RNA interference versus antibody-based PCSK9 inhibition for the prevention of cardiovascular disease: a drug-target Mendelian randomization study.
Cardiovasc Res. 2025 Jul 8;121(7):1066-1075. doi: 10.1093/cvr/cvaf078.
7
[Features of the management of patients during changing the drugs that affect proprotein convertase subtilisin/kexin type 9 (PCSK9)].
Kardiologiia. 2025 Jul 7;65(6):74-80. doi: 10.18087/cardio.2025.6.n2950.
8
Cutting-edge lipid-lowering pharmacological therapies: Improving lipid control beyond statins.
Hipertens Riesgo Vasc. 2025 Apr-Jun;42(2):116-127. doi: 10.1016/j.hipert.2024.12.002. Epub 2025 Jan 6.
9
Anti-PCSK9 antibodies for hypercholesterolaemia: Overview of clinical data and implications for primary care.
Int J Clin Pract. 2017 Aug;71(8). doi: 10.1111/ijcp.12979. Epub 2017 Jul 27.
10
Lowering LDL cholesterol by PCSK9 inhibition: a new era of gene silencing, RNA, and alternative therapies.
Naunyn Schmiedebergs Arch Pharmacol. 2025 Jan 30. doi: 10.1007/s00210-025-03826-4.
本文引用的文献
1
A potent epigenetic editor targeting human PCSK9 for durable reduction of low-density lipoprotein cholesterol levels.
Nat Med. 2025 Apr;31(4):1329-1338. doi: 10.1038/s41591-025-03508-x. Epub 2025 Feb 10.
2
Development of New Genome Editing Tools for the Treatment of Hyperlipidemia.
Cells. 2023 Oct 16;12(20):2466. doi: 10.3390/cells12202466.
3
State Declines in Heart Disease Mortality in the United States, 2000-2019.
NCHS Data Brief. 2021 Dec(425):1-8.
4
CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis.
N Engl J Med. 2021 Aug 5;385(6):493-502. doi: 10.1056/NEJMoa2107454. Epub 2021 Jun 26.
5
Chromothripsis as an on-target consequence of CRISPR-Cas9 genome editing.
Nat Genet. 2021 Jun;53(6):895-905. doi: 10.1038/s41588-021-00838-7. Epub 2021 Apr 12.
6
Genome-wide programmable transcriptional memory by CRISPR-based epigenome editing.
Cell. 2021 Apr 29;184(9):2503-2519.e17. doi: 10.1016/j.cell.2021.03.025. Epub 2021 Apr 9.
7
Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol.
N Engl J Med. 2020 Apr 16;382(16):1507-1519. doi: 10.1056/NEJMoa1912387. Epub 2020 Mar 18.
8
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.
N Engl J Med. 2018 Nov 29;379(22):2097-2107. doi: 10.1056/NEJMoa1801174. Epub 2018 Nov 7.
9
Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis.
JAMA. 2016 Sep 27;316(12):1289-97. doi: 10.1001/jama.2016.13985.
10
2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents.
J Am Coll Cardiol. 2016 Jul 5;68(1):92-125. doi: 10.1016/j.jacc.2016.03.519. Epub 2016 Apr 1.
Zotero 插件